| Abstract text: |
CLL is the most commonly diagnosed type of leukemia. CLL clinical practice guidelines recommend standard therapy based on evidence. Alternative regimens are considered in patients who are not expected to benefit from standard therapy. In the real world CLL is a heterogeneous disease. A lot of factors have to be considered in selecting the best treatment option: CLL related, patient related, treatment outcome is not always clear, and least but not last budgets. New prognostic markers have been identified that may also influence therapeutic approach. Due to increasing potential of newer chemoimmunotherapy combinations, selecting of the right treatment for a patient with CLL has become a task that requires a high degree of professional experience. |
